OxSyBio has announced a formal collaboration agreement with MRC Harwell to develop 3D printed tissues for basic research into disease biology. The partnership aims to bring these tissues to external researchers and partners in 2019, and help to increase the understanding of metabolic diseases such as diabetes and obesity.
The combination of OxSyBio’s 3D printing methods and MRC Harwell’s deep knowledge of mammalian models of disease will make characterised and reproducible 3D printed living tissues available affordably and on-demand.
The partnership will prioritise metabolic diseases, with 3D models that will aid the study of diabetes and obesity. The joint team is creating a range of artificial tissues that can be used in conjunction with, and ultimately, in place of ‘gold standard’ animal derived tissues. These are created as ready-to-use 96-well format plates.
The creation of these novel 3D models was facilitated and supported by the Harwell HealthTec Cluster Proof of Concept Grant Scheme. The resulting technology indicates that could save decades in terms of laboratory time, freeing up scientists from exacting repetitive tasks, allowing them to accelerate other areas of their research.